Paragon 28, Inc. (FNA): Price and Financial Metrics
GET POWR RATINGS... FREE!
FNA Stock Price Chart Interactive Chart >
FNA Price/Volume Stats
Current price | $15.03 | 52-week high | $25.41 |
Prev. close | $15.19 | 52-week low | $12.35 |
Day low | $15.03 | Volume | 9,973 |
Day high | $15.68 | Avg. volume | 165,734 |
50-day MA | $16.92 | Dividend yield | N/A |
200-day MA | $0.00 | Market Cap | 1.15B |
Paragon 28, Inc. (FNA) Company Bio
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, such as gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback ankle fusion plating systems. The company also provides precision guide technology for various procedures consisting of MTP fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot; bunion or hallux valgus correction systems; phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics, such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Further, the company provides hammertoe implants, titanium wedges, and soft tissue fixators, as well as products for the various procedure, such as bunions, flatfoot, fracture fixation, and foot fracture. It serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was incorporated in 2010 and is headquartered in Englewood, Colorado.
Latest FNA News From Around the Web
Below are the latest news stories about Paragon 28 Inc that investors may wish to consider to help them evaluate FNA as an investment opportunity.
What Type Of Shareholders Make Up Paragon 28, Inc.'s (NYSE:FNA) Share Registry?If you want to know who really controls Paragon 28, Inc. ( NYSE:FNA ), then you'll have to look at the makeup of its... |
Paragon 28 acquires Disior Oy for $18MParagon 28 (FNA) has acquired Finland based Disior Oy., a leading three-dimensional analytics pre-operative planning software company focused on the complex foot and ankle… |
Paragon 28 Announces Acquisition of DisiorENGLEWOOD, Colo., January 12, 2022--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the acquisition of Disior Oy., a leading three-dimensional analytics pre-operative planning software company based in Helsinki, Finland, focused on the complex foot and ankle anatomy. |
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), SI-Bone (SIBN – Research Report) and Paragon 28 (FNA – Research Report) with bullish sentiments. Atricure (ATRC) In a report released today, Marie Thibault from BTIG maintained a Buy rating on Atricure, with a price target of $94.00. The company's shares closed last Friday at $61.62. According to TipRanks. |
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021ENGLEWOOD, Colo., January 10, 2022--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "P28"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021. |
FNA Price Returns
1-mo | -18.71% |
3-mo | 2.73% |
6-mo | -28.87% |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | -15.04% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...